+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chronic Urticaria Or Hives - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 152 Pages
  • October 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5189124
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2020, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 7, 8, 6, 1 and 1 respectively.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Chronic Urticaria Or Hives - Overview
  • Chronic Urticaria Or Hives - Therapeutics Development
  • Chronic Urticaria Or Hives - Therapeutics Assessment
  • Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
  • Chronic Urticaria Or Hives - Drug Profiles
  • Chronic Urticaria Or Hives - Dormant Projects
  • Chronic Urticaria Or Hives - Discontinued Products
  • Chronic Urticaria Or Hives - Product Development Milestones
  • Appendix

List of Tables
  • Number of Products under Development for Chronic Urticaria Or Hives, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by Allakos Inc, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by BiOraliX BV, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by BiosanaPharma BV, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by Celldex Therapeutics Inc, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by Celltrion Inc, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by Eli Lilly and Co, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by ELORAC Inc, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by Genentech USA Inc, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by GI Innovation Co Ltd, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by Innate Pharma SA, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by Kolmar Korea Holdings Co Ltd, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by Kyowa Kirin Co Ltd, H2 2020
  • Chronic Urticaria Or Hives - Pipeline by Mabtech Ltd, H2 2020
  • Chronic Urticaria Or Hives - Dormant Projects, H2 2020
  • Chronic Urticaria Or Hives - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Chronic Urticaria Or Hives, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Allakos Inc
  • BiOraliX BV
  • BiosanaPharma BV
  • Celldex Therapeutics Inc
  • Celltrion Inc
  • Eli Lilly and Co
  • ELORAC Inc
  • F. Hoffmann-La Roche Ltd
  • Faes Farma SA
  • Genentech USA Inc
  • GI Innovation Co Ltd
  • GlaxoSmithKline Plc
  • Innate Pharma SA
  • Kolmar Korea Holdings Co Ltd
  • Kyowa Kirin Co Ltd
  • Mabtech Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Mycenax Biotech Inc
  • Novartis AG
  • Oneness Biotech Co Ltd
  • PharmAbcine Inc
  • RAPT Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • STERO Biotechs Ltd
  • Synermore Biologics Co Ltd
  • UCB SA
  • United Biomedical Inc
  • United BioPharma Inc